- Home
- BNZI vs VIVS Comparison
BNZI vs VIVS Comparison
Compare BNZI & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BNZI | VIVS |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6M | 8.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BNZI | VIVS |
|---|---|---|
| Price | $1.41 | $2.15 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $23.00 | N/A |
| AVG Volume (30 Days) | ★ 991.1K | 36.7K |
| Earning Date | 11-14-2025 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,650,176.00 | $140,000.00 |
| Revenue This Year | $185.61 | $42.38 |
| Revenue Next Year | $32.86 | $15.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 147.06 | 35.92 |
| 52 Week Low | $0.92 | $1.41 |
| 52 Week High | $27.00 | $21.96 |
Technical Indicators
Market Signals| Indicator | BNZI | VIVS |
|---|---|---|
| Relative Strength Index (RSI) | 51.62 | 53.58 |
| Support Level | $1.35 | $1.96 |
| Resistance Level | $1.56 | $2.29 |
| Average True Range (ATR) | 0.23 | 0.15 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 47.32 | 70.78 |
Price Performance
Historical ComparisonAbout BNZI Banzai International Inc.
Banzai International Inc is a marketing technology (MarTech) company that produces data-driven marketing and sales solutions for businesses of all sizes. Its mission is to help its customers accomplish their mission by enabling marketing, sales and customer engagement outcomes. The company has two reportable operating segments, Banzai Operating and OpenReel. The company's segments deliver SaaS tools that leverage data, analytics, and AI to provide marketing and sales solutions for business of all size. it derives maximum revenue from Banzai Operating segment. Geographically, it operates in Americas, Europe, Middle East and Africa (EMEA), and Asia Pacific.
About VIVS VivoSim Labs Inc.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.